269 related articles for article (PubMed ID: 22004792)
1. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance.
Zimic M; Fuentes P; Gilman RH; Gutiérrez AH; Kirwan D; Sheen P
Tuberculosis (Edinb); 2012 Jan; 92(1):84-91. PubMed ID: 22004792
[TBL] [Abstract][Full Text] [Related]
2. pncA gene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis.
Sheen P; Lozano K; Gilman RH; Valencia HJ; Loli S; Fuentes P; Grandjean L; Zimic M
Tuberculosis (Edinb); 2013 Sep; 93(5):515-22. PubMed ID: 23867321
[TBL] [Abstract][Full Text] [Related]
3. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.
Khan MT; Malik SI; Ali S; Masood N; Nadeem T; Khan AS; Afzal MT
BMC Infect Dis; 2019 Feb; 19(1):116. PubMed ID: 30728001
[TBL] [Abstract][Full Text] [Related]
4. Metallochaperones Are Needed for Mycobacterium tuberculosis and Escherichia coli Nicotinamidase-Pyrazinamidase Activity.
Sheen P; Monsalve A; Campos J; Huerta R; Antiparra R; Arteaga H; Duran P; Bueno C; Kirwan DE; Gilman RH; Zimic M
J Bacteriol; 2020 Jan; 202(2):. PubMed ID: 31636108
[No Abstract] [Full Text] [Related]
5. Identification of Novel Efflux Proteins Rv0191, Rv3756c, Rv3008, and Rv1667c Involved in Pyrazinamide Resistance in Mycobacterium tuberculosis.
Zhang Y; Zhang J; Cui P; Zhang Y; Zhang W
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584158
[TBL] [Abstract][Full Text] [Related]
6. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.
Zhang Y; Scorpio A; Nikaido H; Sun Z
J Bacteriol; 1999 Apr; 181(7):2044-9. PubMed ID: 10094680
[TBL] [Abstract][Full Text] [Related]
7. Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis.
Sheen P; Ferrer P; Gilman RH; López-Llano J; Fuentes P; Valencia E; Zimic MJ
Tuberculosis (Edinb); 2009 Mar; 89(2):109-13. PubMed ID: 19249243
[TBL] [Abstract][Full Text] [Related]
8. A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis.
Zimic M; Loli S; Gilman RH; Gutierrez A; Fuentes P; Cotrina M; Kirwan D; Sheen P
Microb Drug Resist; 2012 Aug; 18(4):372-5. PubMed ID: 22372927
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.
Jonmalung J; Prammananan T; Leechawengwongs M; Chaiprasert A
BMC Microbiol; 2010 Aug; 10():223. PubMed ID: 20727143
[TBL] [Abstract][Full Text] [Related]
10. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide.
Sun Z; Zhang Y
Antimicrob Agents Chemother; 1999 Mar; 43(3):537-42. PubMed ID: 10049264
[TBL] [Abstract][Full Text] [Related]
11. A quantitative adaptation of the Wayne test for pyrazinamide resistance.
Meinzen C; Proaño A; Gilman RH; Caviedes L; Coronel J; Zimic M; Sheen P
Tuberculosis (Edinb); 2016 Jul; 99():41-46. PubMed ID: 27450003
[TBL] [Abstract][Full Text] [Related]
12. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.
Cheng SJ; Thibert L; Sanchez T; Heifets L; Zhang Y
Antimicrob Agents Chemother; 2000 Mar; 44(3):528-32. PubMed ID: 10681313
[TBL] [Abstract][Full Text] [Related]
13. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.
Miotto P; Cabibbe AM; Feuerriegel S; Casali N; Drobniewski F; Rodionova Y; Bakonyte D; Stakenas P; Pimkina E; Augustynowicz-Kopeć E; Degano M; Ambrosi A; Hoffner S; Mansjö M; Werngren J; Rüsch-Gerdes S; Niemann S; Cirillo DM
mBio; 2014 Oct; 5(5):e01819-14. PubMed ID: 25336456
[TBL] [Abstract][Full Text] [Related]
14. Estimation of pyrazinamidase activity using a cell-free
Rueda D; Bernard C; Gandy L; Capton E; Boudjelloul R; Brossier F; Veziris N; Zimic M; Sougakoff W
Int J Mycobacteriol; 2018; 7(1):16-25. PubMed ID: 29516881
[TBL] [Abstract][Full Text] [Related]
15. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis.
Davies AP; Billington OJ; McHugh TD; Mitchison DA; Gillespie SH
J Clin Microbiol; 2000 Oct; 38(10):3686-8. PubMed ID: 11015384
[TBL] [Abstract][Full Text] [Related]
16. Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR-based in vitro system.
Suzuki Y; Suzuki A; Tamaru A; Katsukawa C; Oda H
J Clin Microbiol; 2002 Feb; 40(2):501-7. PubMed ID: 11825963
[TBL] [Abstract][Full Text] [Related]
17. Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance.
Zimic M; Sheen P; Quiliano M; Gutierrez A; Gilman RH
Infect Genet Evol; 2010 Mar; 10(2):346-9. PubMed ID: 19963078
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity.
Raynaud C; Lanéelle MA; Senaratne RH; Draper P; Lanéelle G; Daffé M
Microbiology (Reading); 1999 Jun; 145 ( Pt 6)():1359-1367. PubMed ID: 10411262
[TBL] [Abstract][Full Text] [Related]
19. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.
Scorpio A; Lindholm-Levy P; Heifets L; Gilman R; Siddiqi S; Cynamon M; Zhang Y
Antimicrob Agents Chemother; 1997 Mar; 41(3):540-3. PubMed ID: 9055989
[TBL] [Abstract][Full Text] [Related]
20. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene.
Bhuju S; Fonseca Lde S; Marsico AG; de Oliveira Vieira GB; Sobral LF; Stehr M; Singh M; Saad MH
Infect Genet Evol; 2013 Oct; 19():1-6. PubMed ID: 23770140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
